United Therapeutics (NASDAQ:UTHR) Given New $687.00 Price Target at JPMorgan Chase & Co.

United Therapeutics (NASDAQ:UTHR) had its target price increased by JPMorgan Chase & Co. from $685.00 to $687.00 in a report published on Thursday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biotechnology company’s stock.

A number of other research firms also recently issued reports on UTHR. Royal Bank Of Canada increased their price objective on shares of United Therapeutics from $701.00 to $704.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research note on Thursday, June 11th. HC Wainwright upped their target price on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Bank of America lowered their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Finally, Morgan Stanley set a $516.00 target price on United Therapeutics in a research report on Thursday, May 7th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $648.33.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $529.53 on Thursday. United Therapeutics has a 1-year low of $272.12 and a 1-year high of $609.35. The company has a 50-day moving average of $548.68 and a 200 day moving average of $531.41. The firm has a market cap of $22.48 billion, a PE ratio of 19.55, a price-to-earnings-growth ratio of 1.76 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. During the same quarter in the previous year, the company earned $6.63 earnings per share. The firm’s revenue was down 1.6% on a year-over-year basis. Sell-side analysts anticipate that United Therapeutics will post 26.63 EPS for the current fiscal year.

Insider Activity

In other United Therapeutics news, Director Jan Malcolm sold 325 shares of United Therapeutics stock in a transaction on Friday, July 10th. The shares were sold at an average price of $550.59, for a total value of $178,941.75. Following the transaction, the director directly owned 450 shares of the company’s stock, valued at approximately $247,765.50. The trade was a 41.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Monday, July 13th. The stock was sold at an average price of $535.99, for a total transaction of $5,091,905.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at $21,714,562.87. This represents a 19.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 513,333 shares of company stock worth $286,933,042. Corporate insiders own 8.60% of the company’s stock.

Institutional Trading of United Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Leuthold Group LLC lifted its stake in shares of United Therapeutics by 41.4% in the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock valued at $5,200,000 after purchasing an additional 3,126 shares during the period. UBS Group AG boosted its holdings in United Therapeutics by 45.3% during the fourth quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock worth $110,045,000 after buying an additional 70,445 shares in the last quarter. Perpetual Ltd acquired a new stake in United Therapeutics during the fourth quarter valued at $1,059,000. SG Americas Securities LLC grew its position in United Therapeutics by 88.6% during the fourth quarter. SG Americas Securities LLC now owns 26,960 shares of the biotechnology company’s stock valued at $13,136,000 after buying an additional 12,663 shares during the period. Finally, Brookstone Capital Management grew its position in United Therapeutics by 25.4% during the fourth quarter. Brookstone Capital Management now owns 6,622 shares of the biotechnology company’s stock valued at $3,227,000 after buying an additional 1,342 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.